ASMBS: Moving Into a New World of Obesity Care

Key Takeaways

• GLP-1 drugs surge, reshaping obesity treatment landscape
• Metabolic surgery remains top for durable weight loss
• Clinicians adopt combined drug‑surgery sequencing for personalized care
• Focus shifts from weight loss to long‑term metabolic health
• Obesity now viewed as chronic disease requiring lifelong management

Pulse Analysis

The 2026 American Society for Metabolic and Bariatric Surgery (ASMBS) meeting in San Antonio marked a turning point for obesity treatment. While bariatric surgery has long been the cornerstone for severe obesity, the conference highlighted a broader, more nuanced view that prioritizes metabolic health over simple weight loss. Speakers emphasized that obesity is a chronic, relapsing condition, prompting a shift toward integrated care pathways that blend surgical and pharmacologic options. This evolution reflects growing evidence that sustained cardiometabolic improvement, quality of life, and longevity are the true endpoints of successful therapy.

GLP‑1 receptor agonists have exploded onto the scene, with prescriptions doubling in the past three years and reshaping patient expectations. These agents deliver modest weight loss and profound glycemic control, making them attractive as first‑line or adjunctive therapy. At ASMBS, surgeons reported using GLP‑1 drugs pre‑operatively to reduce surgical risk, post‑operatively to prevent weight regain, and in some cases as a non‑surgical alternative for patients unwilling or ineligible for surgery. The emerging “sequencing” model leverages the strengths of both modalities, creating a personalized continuum of care.

The convergence of surgery and pharmacotherapy carries significant implications for payers, providers, and policy makers. Reimbursement models must evolve to support combination regimens, while training programs will need curricula that integrate medical weight‑loss strategies with operative techniques. Moreover, the shift toward metabolic health endpoints aligns with value‑based care initiatives, offering a pathway to lower long‑term cardiovascular costs. As the obesity epidemic persists, this integrated approach promises to expand treatment access, improve patient outcomes, and cement metabolic surgery’s role as a first‑line, evidence‑based option rather than a last‑resort.